A Prospective, Non-interventional Study of the Effectiveness, Safety, and Health Related Outcomes in Patients With Moderate to Severe Active Rheumatoid Arthritis Receiving Filgotinib
Latest Information Update: 02 Aug 2024
At a glance
- Drugs Filgotinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms FILOSOPHY
- Sponsors Alfasigma
- 29 Jul 2024 Planned End Date changed from 1 Jul 2025 to 1 Jun 2028.
- 29 Jul 2024 Planned primary completion date changed from 1 Jul 2025 to 1 Jun 2028.
- 14 May 2024 Status changed from recruiting to active, no longer recruiting.